Thus, MEIS2 knockdown increases responsiveness to chemotherapy in multiple myeloma, whereas MEIS2 is downregulated in colorectal cancer patients resistant towards oxaliplatin-based chemotherapy [41, 45]. The gene discussed is MEIS2; the disease is plasma cell myeloma.